A new study presented at the Society of Interventional Radiology’s 37th Annual Scientific Meeting in San Francisco, USA, shows that a lower-dosage CT-guided lung biopsy protocol results in 66% average dose reduction with no difference in nodule size, or biopsy difficulty.
Delcath Systems has announced that Quintiles will provide a specialised team of medical science liaisons to support the launch of the hepatic Chemosat delivery system for the treatment of cancers in the liver in France, Germany, Italy, Netherlands, Spain, Ireland and the United Kingdom. In addition, it will provide medical communication to support patient advocacy, key opinion leader development, and field force materials.
Covidien has announced the launch of the HALO60 ablation catheter, the latest addition to the HALO family of catheters for the endoscopic treatment of Barrett’s esophagus.
SARAH (Sorafenib versus radioembolization in advanced hepatocellular carcinoma) is designed to directly compare the effectiveness of radioembolization with yttrium-90 resin microspheres (Sirtex) versus sorafenib (Bayer HealthCare Pharmaceuticals), a systemic therapy that is the current standard of care for patients with non-operable advanced hepatocellular carcinoma (HCC).
On 15 February, Delcath Systems and the European Institute of Oncology (Instituto Europeo di Oncologia – IEO) introduced the Delcath Hepatic Chemosat Delivery System to media at a press conference and discussed the status of the first European patients treated with the technology.
C. R. Bard, Inc. (NYSE: BCR) today announced that Christopher S. Holland has been named Senior Vice President and Chief Financial Officer, effective May 21, 2012. In this role, Mr. Holland will report directly to Timothy M. Ring, Chairman and Chief Executive Officer. BUSINESS WIRE.
St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced that preliminary data demonstrated the company’s EnligHTN™ renal denervation system was safe and effective for the treatment of resistant hypertension. The study demonstrated that on average patients with resistant hypertension experience a systolic blood pressure reduction of 28 points after 30 days.
St. Jude Medical, Inc. (NYSE:STJ ), a global medical device company, today announced CE Mark Approval and launch of its EnligHTN™ renal denervation system during EuroPCR. Renal denervation is a specialized ablation procedure that has been clinically proven to reduce blood pressure in patients with hypertension, or high blood pressure, that is resistant to medical therapy. Clinical data from the EnligHTN I trial about the safety and efficacy of the company’s renal denervation technology will be presented on Wednesday.
Boston Scientific Corporation (NYSE: BSX) announces CE Mark and European market launch of the Innova Self-Expanding Bare-Metal Stent System, which is designed to treat peripheral vascular lesions in arteries above the knee, specifically the superficial femoral artery (SFA) and proximal popliteal artery (PPA). The company plans to launch the product immediately in Europe and other CE Mark countries.
ReCor Medical, an emerging medical device company, announced today that it has completed enrollment in the REDUCE 15-patient pilot clinical study of its PARADISE (Percutaneous Renal Denervation System) ultrasound platform for achieving renal denervation. PARADISE, which is CE-marked, is designed to treat patients with ‘resistant’ hypertension (“HTN”), a major risk factor for cardiovascular disease.
CryoLife, Inc. (CRY), a leading tissue processing and medical device company focused on cardiac and vascular surgery, announced today that it has signed a definitive agreement to acquire Hemosphere, Inc., a privately-held medical device company that has developed and markets the HeRO (Hemodialysis Reliable Outflow) Graft. The HeRO Graft is a proprietary graft-based solution for end-stage renal disease (ESRD) hemodialysis patients with limited access options and central venous obstruction.
Covidien (NYSE: COV ), a leading global provider of healthcare products, will unveil its new OneShot™ renal denervation system at the EuroPCR congress in Paris, France, on May 16, 2012. Adding to the Company’s broad and growing vascular therapies portfolio, the OneShot system is designed to treat patients with hypertension who are not responsive to traditional medical therapy.
In order to meet a need for transcatheter embolic agents that can be precisely placed, optimally conformed, with complete and durable occlusion, and maximal safety profile, several notable developments have occurred with respect to coil-type embolization. A generic overview of commercially available devices follows.
El Hospital Universitario de La Ribera, líder en la aplicación de la radiofrecuencia para el tratamiento de tumores pulmonares. El centro hospitalario ha celebrado una sesión de trabajo en la que han participado destacados profesionales de varias comunidades autónomas.
João Martins Pisco, professor and chair, Department of Radiology, Lisbon, Portugal, and one of the pioneers of the procedure, tells Interventional News about his personal experience with prostatic artery embolization.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos